Kiniksa Pharmaceuticals International, plc
KNSA
$56.51
-$2.03-3.47%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 55.51% | 64.95% | 61.17% | 44.34% | 72.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 55.51% | 64.95% | 61.17% | 44.34% | 72.54% |
| Cost of Revenue | 56.30% | 37.66% | 69.10% | 67.76% | 96.46% |
| Gross Profit | 54.86% | 96.90% | 54.93% | 29.39% | 57.05% |
| SG&A Expenses | 40.48% | 40.06% | 5.83% | 10.54% | 12.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.58% | 28.57% | 28.69% | 25.65% | 29.16% |
| Operating Income | 120.52% | 202.43% | 348.72% | 17,330.77% | 180.23% |
| Income Before Tax | 109.96% | 237.05% | 477.13% | 892.93% | 209.03% |
| Income Tax Expenses | 43.60% | 212.10% | 58.81% | -18.79% | 104.96% |
| Earnings from Continuing Operations | 164.57% | 259.75% | 245.24% | 556.29% | 148.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 164.57% | 259.75% | 245.24% | 556.29% | 148.23% |
| EBIT | 120.52% | 202.43% | 348.72% | 17,330.77% | 180.23% |
| EBITDA | 118.37% | 207.07% | 363.58% | 6,455.27% | 184.70% |
| EPS Basic | 151.32% | 252.07% | 239.38% | 541.45% | 146.89% |
| Normalized Basic EPS | 99.33% | 230.47% | 462.36% | 859.11% | 206.02% |
| EPS Diluted | 145.45% | 247.19% | 227.78% | 483.33% | 143.89% |
| Normalized Diluted EPS | 93.97% | 221.54% | 438.28% | 803.45% | 201.19% |
| Average Basic Shares Outstanding | 5.33% | 5.04% | 4.17% | 3.43% | 2.85% |
| Average Diluted Shares Outstanding | 8.23% | 12.79% | 11.58% | 9.77% | 7.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |